Healthcare
Ionis Pharmaceuticals, Inc.(IONS)
Live Price
Offline$74.12
-0.26% today
1Y Change
+89.97%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $12.34B
- Revenue Growth
- +33.9%
- EPS Growth
- +21.7%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Ionis Pharmaceuticals, Inc. (IONS) is a Healthcare stock with a market cap of $12.34B and listed on NASDAQ. The stock last traded around $74.12 and up 90.0% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of +33.9%, EPS growth of +21.7%, a dividend yield of 0.0%. What stands out right now is revenue +33.9%, EPS +21.7%, free cash flow +41.4% with operating margin -33.3% and ROIC -11.1%. Valuation already assumes a fairly strong business story at price/sales 11.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines IONS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+33.9% vs +7.6% peer median
Operating Margin
Below sector median
-33.3% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 29, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +33.9% and EPS at +21.7%, with operating margin around -33.3%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1.6% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 29, 2026 | โ | -0.1% | +2.7% | +3.3% |
2026 Feb 25, 2026 | -14.0% | -0.4% | -1.8% | -10.2% |
2025 Oct 29, 2025 | +47.0% | +3.2% | +3.9% | +15.1% |
Benchmark Edge
IONS vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
IONS
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
IONS Max Drawdown
-19.45%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for IONS and SPY.
Company Overview
Ionis Pharmaceuticals, Inc.
NASDAQ Global Select
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
- Leadership
- Brett Monia
- IPO Date
- May 17, 1991
- Employees
- 1.1k
- Street Address
- 2855 Gazelle Court
- Mailing
- Carlsbad, CA, 92010
- Region
- Carlsbad, CA, US
- Reporting Currency
- USD
- Investor Line
- 760 931 9200
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 3.2
- Price/Sales
- 11.7
- Price/Book
- 25.1
Growth
- Revenue
- +33.9%
- EPS
- +21.7%
- Free Cash Flow
- +41.4%
Profitability
- Gross Margin
- 98.3%
- Operating Margin
- -33.3%
- Net Margin
- -30.9%
- ROE
- -58.6%
- ROIC
- -11.1%
Balance Sheet
- Debt/Equity
- 4.56
- Current Ratio
- 4.10
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.